Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL742131 | 1.00 | CYP11B1 (0.42) | CYP11B1CYP11B2TRIM24TRIM33SIRT2 | |
| SCHEMBL27865425 | 0.84 | CYP11B1 (0.47) | CYP11B1CYP11B2TRIM24TRIM33PARP1 | |
| SCHEMBL601689 | 0.84 | LIPG (0.47) | CYP11B1CYP11B2LIPG | |
| SCHEMBL11521698 | 0.84 | LIPG (0.47) | CYP11B1CYP11B2LIPG | |
| SCHEMBL2184230 | 0.84 | LIPG (0.47) | CYP11B1CYP11B2LIPG | |
| SCHEMBL5494445 | 0.84 | LIPG (0.47) | CYP11B1CYP11B2LIPG | |
| SCHEMBL31575912 | 0.84 | LIPG (0.47) | CYP11B1CYP11B2LIPG | |
| Water SCHEMBL28194264 | 0.82 | LIPG (0.46) | CYP11B1CYP11B2LIPG | |
| SCHEMBL30950077 | 0.79 | CYP11B1 (0.44) | CYP11B1CYP11B2TRIM24TRIM33PARP1 | |
| SCHEMBL27938298 | 0.79 | CYP11B1 (0.44) | CYP11B1CYP11B2TRIM24TRIM33PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-05-17 | — | — | US | disclosed |
| EP-2430074-A1 | DI-SUBSTITUTED PYRIDINIUM POLYMERS AND SYNTHESIS THEREOF | University Court Of The University Of Aberdeen (GB) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010086652-A1 | DI-SUBSTITUTED PYRIDINIUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | PDXK, RAD54L, CDKL5 | CYP11B1 4687/4885CYP11B2 4549/4885TRIM24 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.